1. Diehl MA, Psychosocial factors that predict adherence to cancer therapy: analysis of depression, self-efficacy, and social support. [Dissertation]. Texas. Tech University. 2014.

2. Holland J, Weiss T R. History of psycho-oncology, 2nd ed. New York: Oxford University Press; 2010: 3 -12.

3. World Health Organization. Adherence to Long-term Therapies: Evidence for Action. Geneva: Switzerland; 2003.

4. Conn VS, Enriquez M, Ruppar TM, Chan KC. Meta-analyses of theory use in medication adherence intervention research. Am J Health Behav 2016; 40(2): 155–71.

5. Richards CS, O’Hara MW. The Oxford handbook of depression and comorbidity. New York: Oxford University Press; 2014.

6. Phatakand J, Thomas III. Relationship between beliefs about medications and non-adherence to prescribed chronic medications. Ann Pharmacother 2006; 40(10): 1737–42.

7. Brett J, Boulton M, Fenlon D, Hulbert-Williams NJ, Walter FM, Donnelly P, et al. Adjuvant endocrine therapy after breast cancer: a qualitative study of factors associated with adherence. Patient Prefer Adherence 2018; 12: 291–300.

8. Hanghøj S, Boisen KA. Self-reported barriers to medication adherence among chronically ill adolescents: a systematic review. J Adolesc Health 2014; 54(2): 121–38.

9. Chan A, Low XH, Yap KY. Assessment of the relationship between adherence with antiemetic drug therapy and control of nausea and vomiting in breast cancer patients receiving anthracycline-based chemotherapy. J Manag Care Pharm 2012; 18(5): 385-94.

10. de Souza BF, de Moraes JA, Inocenti A, dos Santos MA, Silva AE, Miasso AI. Women with breast cancer taking chemotherapy: depression symptoms and treatment adherence. Rev Latino-Am Enfermagem 2014; 22(5): 866-73.

11. Clyne W, Mshelia C, McLachlan S, Jones P, de Geest S, Ruppar T, et al. A multinational cross-sectional survey of the management of patient medication adherence by European healthcare professionals. BMJ Open 2016; 6: 96-106.

12. Nieuwlaat R, Wilczynski N, Navarro T, Hobson N, Jeffery R, Keepanasseril A, et al. Interventions for enhancing medication adherence. Cochrane Database Syst Rev 2014; 11(2).

13. Sanderson. Health psychology. Translated by Jomhari, et al. Karaj: Sarafraz Press. 2013.

14. Sookhak F, Zolfaghari M, Asadi Noghabi AA, Haghani H. Effect of a cognitive-behavioral intervention on medication adherence in patients’ undergoing hemodialysis. Hayat, J Sch Nurs Midw Tehran Univ Med Sci 2014; 20(3): 85-94. [in Persian]

15. Ramesh A, Rajanandh S, Thanmayee G, SalaghaMerin S, Suresh K, Srinivas S. Impact of patient counseling on medication adherence, beliefs and satisfaction about oral chemotherapies in patients with metastatic cancer at a super specialty hospital. Int J Cancer Res 2015; 11(3): 128-35.

16. Markovitz L, Drysdale N, Bettencourt B. The relationship between risk factors and medication adherence among breast cancer survivors: what explanatory role might depression play? Psychooncology 2017; 26: 2294–99.

17. Hershman DL, Shao T, Kushi LH, Buono D, Tsai WY, Fehrenbacher L, et al. Early discontinuation and non-adherence to adjuvant hormonal therapy are associated with increased mortality in women with breast cancer. Breast Cancer Res Treat 2011; 126(2): 529–37.

18. Chaudhry HJ, McDermott B. Recognizing and improving patient non-adherence to statin therapy. Curr Atheroscler Rep 2008; 10(1): 19–24.

19. Urquhart J. Pharmionics: research on what patients do with prescription drugs. Pharmaco epidemiol Drug Saf 2004; 13(9): 587–90.

20. Brown MT, Bussell JK. Medication adherence: who cares? Mayo Clin Proc 2011; 86(4): 304–14.

21. Blalock SJ. The theoretical basis for practice-relevant medication use research: patient-centered/ behavioral theories. Res Social Adm Pharm 2011; 7(4): 317–29.

22. Bahmani B, Etemadi A, Shafiabadi A, Delavar A, Ghanbari Motlagh A. Cognitive-existential group therapy and cognitive therapy-oriented training in breast cancer patients. J Develop Psychol 2008; 6(23): 201-14. [in Persian]

23. Moshier SJ, Otto M. Behavioral activation treatment for major depression: a randomized trial of the efficacy of augmentation with cognitive control training. J Affec Disor 2017; 210: 265-8.

24. Hopko DR, Lejuez CW, Ruggiero KJ, Eifert GH. Contemporary behavioral activation treatments for depression: procedures, principles, progress. Clin Psychol Rev 2003; 23: 699-717.

25. Chartier JS, Provencher MD. Behavioral activation for depression: efficacy, effectiveness and dissemination. J Affec Disor 2013; 145(3): 292-9.

26. Hopko DR, Lejuez CW. A cancer patient’s guide to overcoming depression and anxiety: getting through treatment and getting back to your life. Oakland, CA: New Harbinger; 2007.

27. Martell, Dimidjian, Hermann, Down. A practical guide to behavioral activation for the treatment of depression. Translated by Mohammadkhani, et al. Tehran: Varaye Danesh; 2010.

28. Ekers D, Richards D, Gilbody S. A meta-analysis of randomized trials of behavioural treatment of depression. Psychological Medicine: A Psychiatr Rehabil J 2008; 38: 611-23.

29. Hopko DR, Lejuez CW, Ryba MM, Shorter RL, Bell JL. Support for the efficacy of behavioural activation in treating anxiety in breast cancer patients. Clin PsyChologist 2016; 20(1): 17-26.

30. Shareh H. Effectiveness of behavioral activation group therapy on attributional styles, depression, and quality of life in women with breast cancer. J Funda Ment Health 2016; 18(4): 179-88. [in Persian]

31. Cohen J. Statistical power analysis for the behavioral sciences, 2nd ed. United States of America: Lawrence Erlbaum Associates; 1988. 310-11.

32. Daughters SB, Braun AR, Sargeant MN, Reynolds EK, Hopko DR, Blanco C, et al. Effectiveness of a brief behavioral treatment for inner-city illicit drug users with elevated depressive symptoms: the life enhancement treatment for substance abuse. J Clin Psychiatry 2008; 69(1): 122-9.

33. Dimidjian S, Hollon SD, Dobson S, Schmaling KB, Kohlenberg RJ, Addis ME, et al. Randomized trial of behavioral activation, cognitive therapy, and antidepressant medication in the acute treatment of adults with major depression. J Consult Clin Psychol 2006; 74(4): 658–70.

34. Lejuez CW, Hopko DR, Acierno R, Daughters SB, Pagoto SL. Ten-year revision of the brief behavioral activation treatment for depression (BATD): revised treatment manual (BATD-R). J

35. Behav Modif 2011; 35(2): 111-61.

36. Morisky DE, Ang A, KrouselWood M, Ward H. Predictive validity of a medication adherence measure in an outpatient setting. J Clin Hypertens 2008; 10(5): 348-354.

37. Bocaeian M, Evaluation of personality traits and memory performance and demographic personality traits as predictors of medication adherence in cardiac patients. [Dissertation]. Masters Degree in Clinical Psychology. Department of Psychology, Shiraz University. 2013.

38. Magidson JF, Seitz-Brown CJ, Safren SA, Daughters SB. Implementing behavioral activation and life-steps for depression and HIV medication adherence in a community health center. Cogn Behav Pract 2014; 21(4): 386-403.

39. Tull MT, Berghoff CR, BardeenR, Schoenleber M, Konkle-Parker DJ. An initial open trial of a brief behavioral activation treatment for depression and medication adherence in HIV-infected patients. Behav Modif 2018; 42(2): 196-209.

40. Armento M, Hopko D. Behavioral activation of a breast cancer patient with co-existent major depression and generalized anxiety disorder. Clin Case Stud 2009; 8(1): 25−37.

41. Crosby R, Noar SM. Theory development in health promotion: are we there yet? J Behav Med 2010; 33(4): 259–63.

42. Adefolalu AO. Cognitive behavioral theories and adherence: application and relevance in antiretroviral therapy. S Afr J HIV Med 2018; 19(1): 762-9.